Speaker:
Todd Anderson. Vice Dean. Cumming School of MediCine. University of Calgary.
Dr. Todd Anderson is a Professor of Cardiac Sciences at the University of Calgary. He is the former Head of the Department of Cardiac Sciences, and former Director of the Libin Cardiovascular Institute of Alberta. He has assumed a new role as the Vice Dean of the Cumming School of Medicine. His current research interests include the treatment of dyslipidemia and generation of lipid guidelines, the evaluation of appropriateness in clinical care delivery and the assessment of vascular function in health and disease particularly in women with microvascular angina.
Overview:
Abnormalities of lipoproteins are a major cause of ASCVD risk in Canada with at least 1/3 of Canadians having sub-optimal treatment of this risk factor. Even in subjects with previous ASCVD less than 50% of patients are at target levels of atherogenic lipoproteins. The updated CCS dyslipidemia guidelines has addressed a number of PICO questions that will aid clinicians in decreasing atherogenic risk. Laboratory medicine plays an important role with lipid reporting in helping clinicians understand when treatment might be required for a particular lipid value. We will review the current guidelines and discuss new approaches to the role of laboratory medicine in improving the current treatment gap that exists in Canada
Objectives:
At the end of this activity, participants will be able to:
- At the conclusion of this session, participants will understand the current CCS dyslipidemia guidelines for lipoprotein testing and treatment to reduce atherosclerotic CV risk
- At the conclusion of this session, participants will have explore d the role of laboratory medicine to aid primary care providers in ASCVD risk determination and optimal treatment of individuals at risk